siehe Kurs:
old.nasdaq.com/de/symbol/elox/after-hours
und das steckt dahinter:
2. Eloxx To Resume Cystic Fibrosis Trial After Brief Pause Due To Pandemic
Eloxx Pharmaceuticals Inc. (ELOX) has resumed enrollment in its phase II clinical trial for ELX-02 in cystic fibrosis in Israel and Europe, after being temporarily paused in response to the COVID-19 pandemic in late March. However, the U.S. trial remains temporarily paused due to the pandemic.
Gregory Williams, Chief Executive Officer of Eloxx, said, "We remain committed to completing enrollment in our Phase 2 proof of concept clinical trial program and reporting top-line data as soon as feasible. We will provide further updates as they become available."
ELOX closed Wednesday's trading at $3.05, down 2.24%. In after-hours, the stock gained 41.31% and was at $4.31.
www.rttnews.com/3104466/...rx-to-continue-covid-19-trial.aspx
www.eloxxpharma.com/pipeline/
old.nasdaq.com/de/symbol/elox/after-hours
und das steckt dahinter:
2. Eloxx To Resume Cystic Fibrosis Trial After Brief Pause Due To Pandemic
Eloxx Pharmaceuticals Inc. (ELOX) has resumed enrollment in its phase II clinical trial for ELX-02 in cystic fibrosis in Israel and Europe, after being temporarily paused in response to the COVID-19 pandemic in late March. However, the U.S. trial remains temporarily paused due to the pandemic.
Gregory Williams, Chief Executive Officer of Eloxx, said, "We remain committed to completing enrollment in our Phase 2 proof of concept clinical trial program and reporting top-line data as soon as feasible. We will provide further updates as they become available."
ELOX closed Wednesday's trading at $3.05, down 2.24%. In after-hours, the stock gained 41.31% and was at $4.31.
www.rttnews.com/3104466/...rx-to-continue-covid-19-trial.aspx
www.eloxxpharma.com/pipeline/
